New tools to help identify potential targets in autoimmune diseases
Unexplored proteins could be targets for new drugs to treat autoimmune and other diseases, if only we knew more about them. ULTRA-DD has brought us a few steps closer.
Site Search
Site Search
Displaying results 231 - 240 of 893
ECSEL JU launches Call for proposals on decentralised clinical trials
ECSEL JU, the joint undertaking for electronic components and systems, has launched a Call for proposals on decentralised clinical trials that would complement the work of IMI’s Trials@Home project. IMI and ECSEL JU have been sharing information on their projects, and exploring ...
IMI2 - Call 23
IMI2 - Call 23 was launched on 23 June 2020 with the following topics: Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial ...
IMI2 - Call 22
IMI2 - Call 22 was launched on 23 June 2020 with the following topic: Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities More information can be found in IMI's press release and in the Call text. Other relevant documents can be found on the IMI2 ...
Proposed ‘clustering’ of patients offers hope for better understanding of autoimmune diseases
PRECISESADS’ findings show that despite being diagnosed with an array of autoimmune diseases, patients can be grouped according to molecular patterns
Unravelling the enigma of autoimmune diseases
Diseases that involve the immune system going rogue share common molecular patterns - we’re slowly but surely teasing them out
Focus on: FAIRified data
In May, we focussed on the FAIR principles of data management.
Crucial step towards EC regulatory approval of IMI-funded J&J Ebola vaccine
Studies indicate that the vaccine regimen is well tolerated, with robust and durable immune responses to the Zaire ebolavirus strain.
More - and better - patient data, whatever the disease
The generic architecture of RADAR-Base forms a reusable, flexible IT platform that allows for the remote monitoring of different diseases and conditions using a large variety of technologies.
101st Edition – May 2020
Table of contents:
- IMI2 – Calls 22 and 23: updated topics available and webinar registration open
- IMI announces COVID projects, boosts funding pot to EUR 72 million
- An open letter in response to the GHA/CEO report on IMI
- IMI’s Pierre Meulien: When data is FAIR, citizens ultimately reap the benefit
- News from the projects